Indication
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating respiratory disorder primarily affecting adults exposed to inhaled noxious particles or gases, most commonly tobacco smoke or occupational pollutants. Read more about Chronic obstructive pulmonary disease
7 drugs 5 manufacturers
Drugs that treat it
Common Chronic obstructive pulmonary disease therapies.
YUPELRI (revefenacin)
DUPIXENT PEN (dupilumab)
DUPIXENT SYRINGE (dupilumab)
OHTUVAYRE (ensifentrine)
YUPELRI (revefenacin)
OHTUVAYRE (ensifentrine)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic obstructive pulmonary disease (COPD) is a progressive, debilitating respiratory disorder primarily affecting adults exposed to inhaled noxious particles or gases, most commonly tobacco smoke or occupational pollutants.
Pathophysiologically, it involves persistent airway inflammation, small-airway narrowing from obstructive bronchiolitis, and alveolar wall destruction resulting in emphysema.
These structural abnormalities cause loss of elastic recoil, hyperinflation, and persistent, not fully reversible airflow limitation.
Clinically, affected patients present with worsening exertional dyspnea, chronic cough, excess sputum production, and periodic acute exacerbations that contribute to systemic impairment.
- nih.gov
Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating respiratory disorder primarily affecting adults exposed to inhaled noxious particles or gases, most commonly tobacco smoke or occupational pollutants Pathophysiologically, it involves persistent airway inflammation, small-airway narrowing from obstructive bronchiolitis, and alveolar wall destruction resulting in emphysema Clinically, affected patients present with worsening exertional dyspnea, chronic cough, excess sputu...
- nih.gov
Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating respiratory disorder primarily affecting adults exposed to inhaled noxious particles or gases, most commonly tobacco smoke or occupational pollutants
- goldcopd.org
Pathophysiologically, it involves persistent airway inflammation, small-airway narrowing from obstructive bronchiolitis, and alveolar wall destruction resulting in emphysema These structural abnormalities cause loss of elastic recoil, hyperinflation, and persistent, not fully reversible airflow limitation Clinically, affected patients present with worsening exertional dyspnea, chronic cough, excess sputum production, and periodic acute exacerbations that contribute to systemic impairment
- thoracic.org
These structural abnormalities cause loss of elastic recoil, hyperinflation, and persistent, not fully reversible airflow limitation
Personalize your experience
Follow Chronic obstructive pulmonary disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.